Description
The ProbeSeq Amyloid-Beta (Aβ) Nanobody is a recombinant single-domain antibody (VHH) engineered for high-affinity and selective binding to human amyloid-beta peptides, including aggregation-associated forms involved in neurodegenerative disease pathology. This nanobody supports research-use assay development, neurodegeneration biomarker detection, and advanced biosensor integration.
Amyloid-beta accumulation and aggregation are hallmark features of Alzheimer’s disease and are widely studied in neurodegenerative research. Detection of soluble and aggregated Aβ species is critical for disease mechanism studies, therapeutic development, and early diagnostic technology development.
Derived from camelid heavy-chain antibody architecture, this nanobody consists of a single monomeric VHH domain (~15 kDa) providing strong antigen recognition, rapid binding kinetics, and exceptional structural stability. Compared with conventional antibodies, nanobodies offer superior thermal stability, efficient surface immobilization, and reduced steric hindrance, enabling high-performance detection in electrochemical biosensors, microfluidic platforms, and miniaturized diagnostic systems.
Typical assay workflows use sample input volumes ranging from approximately 5–50 µL depending on platform configuration and detection method. The nanobody is compatible with serum, plasma, cerebrospinal fluid, brain lysates, and buffered biological samples following appropriate assay optimization.
What’s Included
Recombinant anti-Amyloid-Beta single-domain VHH nanobody
Sequence and expression documentation for research traceability
Reconstitution and handling guidelines
Custom affinity tags (His-tag, biotin, Fc fusion), labeling options, and bulk production available upon request
Target Strategy
Engineered for high binding specificity to amyloid-beta peptide epitopes
Recognition of aggregation-associated forms
Minimal cross-reactivity with unrelated neuronal proteins
Compatible with biosensor surface functionalization and immunoassay workflows
Product Format
Lyophilized format
Delivered dry for enhanced stability
Reconstitute in PBS or preferred buffer
Solution format
Supplied in PBS-based storage buffer
Typical concentration range 0.5–1 mg/mL
Tagged variants available upon request
Performance Orientation
Electrochemical biosensors
Neurodegeneration biomarker detection platforms
Microfluidic and lab-on-chip systems
Surface immobilization workflows
Optical and fluorescence detection platforms
Point-of-care neurological diagnostic research devices
Quality Control
Sequence confirmation
Purity validation (SDS-PAGE / chromatography)
Binding verification testing
Concentration determination
Manufacturing quality review
Certificate of Analysis (CoA) available upon request
Applications
Alzheimer’s disease biomarker research
Neurodegeneration mechanism studies
Protein aggregation research
Immunoassay and biosensor development
Microfluidic diagnostic platform integration
Point-of-care neurological monitoring research
Storage
Store at –20 °C for long-term storage or 4 °C for short-term use.
Lyophilized nanobody stable for up to 12 months under recommended conditions. Avoid repeated freeze–thaw cycles.
